Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Gains from Sales and Divestitures (2021 - 2025)

Journey Medical (DERM) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $927446.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures rose 3.75% year-over-year to $927446.0, compared with a TTM value of $927446.0 through Sep 2025, up 3.75%, and an annual FY2024 reading of $1.1 million, up 45.53% over the prior year.
  • Gains from Sales and Divestitures was $927446.0 for Q3 2025 at Journey Medical, up from $324159.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.1 million in Q4 2024 and bottomed at $2000.0 in Q1 2022.
  • Average Gains from Sales and Divestitures over 5 years is $395161.2, with a median of $287951.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures soared 3333.1% in 2023, then tumbled 76.11% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $136500.0 in 2021, then soared by 115.17% to $293707.0 in 2022, then surged by 147.61% to $727249.0 in 2023, then soared by 45.53% to $1.1 million in 2024, then dropped by 12.37% to $927446.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for DERM at $927446.0 in Q3 2025, $324159.0 in Q2 2025, and $50421.0 in Q1 2025.